Advertisement
DALLAS, Jan. 23, 2015 /PRNewswire-iReach/ -- The report "Insulin Resistance – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Insulin Resistance, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insulin Resistance and special features on late-stage and discontinued projects.
Photo - http://photos.prnewswire.com/prnh/20150123/171006
Insulin resistance is a physiological condition in which cells fail to respond to the normal actions of the hormone insulin. Insulin resistance may be part of the metabolic syndrome and it has been associated with higher risk of developing heart disease. Insulin resistance precedes the development of type 2 diabetes. Insulin resistance is associated with other medical conditions, including fatty liver, arteriosclerosis, acanthosis nigricans, skin tags, and reproductive abnormalities in women.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269574 . (This is a premium report priced at US$2000 for a single user License.)
Companies discussed in this Insulin Resistance – Pipeline Review, H1 2015 report include AUS Bio Limited, Genfit SA, GlaxoSmithKline plc, Hadasit Medical Research Services & Development Ltd, Mertiva AB, Mochida Pharmaceutical Co., Ltd., Novartis AG, Prometheon Pharma, LLC, Sanofi, Thetis Pharmaceuticals LLC.
Scope of Insulin Resistance – Pipeline Review, H1 2015 covers: a snapshot of the global therapeutic landscape of Insulin Resistance; reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities; reviews key players involved in the therapeutics development for Insulin Resistance and enlists all their major and minor projects; report summarizes all the dormant and discontinued pipeline projects; A review of the Insulin Resistance products under development by companies and universities/research institutes based on information derived from company and industry-specific sources; Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages; A detailed assessment of monotherapy and combination therapy pipeline projects; Coverage of the Insulin Resistance pipeline on the basis of target, MoA, route of administration and molecule type as well as Latest news and deals relating related to pipeline products.
Inquire before Buying @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=269574 . (This is a premium report priced at US$2000 for a single user License.)
Global Markets Direct report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information.
Reasons to buy
Diabetic Neuropathic Pain – Pipeline Review, H1 2015 - This report provides comprehensive information on the therapeutic development for Diabetic Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathic Pain and special features on late-stage and discontinued projects.
Diabetic Peripheral Neuropathy – Pipeline Review, H1 2015 @ http://www.rnrmarketresearch.com/diabetic-peripheral-neuropathy-pipeline-review-h1-2015-market-report.html .
Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 – Increasing Uptake of Novel Drug Classes to Drive Market Growth: The report provides insights into type 2 diabetes in the Asia-Pacific (APAC) markets of China, India, Japan and Australia. The report estimates the market size for 2013 and provides a forecast until 2020, and covers disease epidemiology, treatment algorithms, and treatment use patterns. It also provides in-depth analysis of the pipeline molecules, clinical trial failure rates, and recent deals. The report has been built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis carried out by GBI Research's team of industry experts.
About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers. Call +1 888 391 5441 with your research requirements or email the details on [email protected] This e-mail address is being protected from spambots. You need JavaScript enabled to view it and we would be happy to help you find the business intelligence that you need.
Media Contact: Ritesh Tiwari, RnR Market Research, +1888391544, [email protected]
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE RnR Market Research
Advertisement
Photo - http://photos.prnewswire.com/prnh/20150123/171006
Insulin resistance is a physiological condition in which cells fail to respond to the normal actions of the hormone insulin. Insulin resistance may be part of the metabolic syndrome and it has been associated with higher risk of developing heart disease. Insulin resistance precedes the development of type 2 diabetes. Insulin resistance is associated with other medical conditions, including fatty liver, arteriosclerosis, acanthosis nigricans, skin tags, and reproductive abnormalities in women.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269574 . (This is a premium report priced at US$2000 for a single user License.)
Companies discussed in this Insulin Resistance – Pipeline Review, H1 2015 report include AUS Bio Limited, Genfit SA, GlaxoSmithKline plc, Hadasit Medical Research Services & Development Ltd, Mertiva AB, Mochida Pharmaceutical Co., Ltd., Novartis AG, Prometheon Pharma, LLC, Sanofi, Thetis Pharmaceuticals LLC.
Scope of Insulin Resistance – Pipeline Review, H1 2015 covers: a snapshot of the global therapeutic landscape of Insulin Resistance; reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities; reviews key players involved in the therapeutics development for Insulin Resistance and enlists all their major and minor projects; report summarizes all the dormant and discontinued pipeline projects; A review of the Insulin Resistance products under development by companies and universities/research institutes based on information derived from company and industry-specific sources; Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages; A detailed assessment of monotherapy and combination therapy pipeline projects; Coverage of the Insulin Resistance pipeline on the basis of target, MoA, route of administration and molecule type as well as Latest news and deals relating related to pipeline products.
Inquire before Buying @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=269574 . (This is a premium report priced at US$2000 for a single user License.)
Global Markets Direct report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information.
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companiesIdentify and understand important and diverse types of therapeutics under development for Insulin Resistance
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Insulin Resistance pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Diabetic Neuropathic Pain – Pipeline Review, H1 2015 - This report provides comprehensive information on the therapeutic development for Diabetic Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathic Pain and special features on late-stage and discontinued projects.
Diabetic Peripheral Neuropathy – Pipeline Review, H1 2015 @ http://www.rnrmarketresearch.com/diabetic-peripheral-neuropathy-pipeline-review-h1-2015-market-report.html .
Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 – Increasing Uptake of Novel Drug Classes to Drive Market Growth: The report provides insights into type 2 diabetes in the Asia-Pacific (APAC) markets of China, India, Japan and Australia. The report estimates the market size for 2013 and provides a forecast until 2020, and covers disease epidemiology, treatment algorithms, and treatment use patterns. It also provides in-depth analysis of the pipeline molecules, clinical trial failure rates, and recent deals. The report has been built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis carried out by GBI Research's team of industry experts.
About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers. Call +1 888 391 5441 with your research requirements or email the details on [email protected] This e-mail address is being protected from spambots. You need JavaScript enabled to view it and we would be happy to help you find the business intelligence that you need.
Media Contact: Ritesh Tiwari, RnR Market Research, +1888391544, [email protected]
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE RnR Market Research
